Literature DB >> 26759239

Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.

Varun V Prabhu1, Bo Hong2, Joshua E Allen2, Shengliang Zhang1, Amriti R Lulla1, David T Dicker1, Wafik S El-Deiry3.   

Abstract

Tumor suppressor p53 is frequently mutated or inactivated in colorectal cancer. In contrast, p53 family member p73 is rarely mutated in colorectal cancer and p73 activation elicits p53-like tumor suppression. Colorectal cancer stem cells (CRCSC) comprise a rare self-renewing subpopulation that contributes to tumor maintenance and chemoresistance. p53 restoration is known to target CRCSCs, but p73 restoration in CRCSCs has not been examined. In this study, we investigated the effects of the small-molecule prodigiosin, which restores the p53 pathway in tumor cells via p73 activation, on CRCSCs in vitro and in vivo Prodigiosin prevented colonosphere formation independent of p53 status and reduced the viability of self-renewing, 5-fluorouracil-resistant Aldefluor positive [Aldefluor(+)] CRCSCs in vitro Furthermore, prodigiosin inhibited the growth of xenograft tumors initiated with Aldefluor+ cells without toxic effects and limited the tumorigenic potential of these cells. Consistently, prodigiosin induced activation of a p53-responsive luciferase reporter in colonospheres, Aldefluor(+) cells, and tumor xenografts. Mechanistic studies revealed that prodigiosin increased the levels of p73 and reduced levels of the oncogenic N-terminally truncated isoform ΔNp73 in Aldefluor(+) cells. Accordingly, p73 knockdown or ΔNp73 overexpression suppressed prodigiosin-mediated inhibition of colonosphere formation. Moreover, prodigiosin increased levels of the transcription factor c-Jun, a regulator of p73 and ΔNp73, in both the cytoplasm and nucleus. c-Jun knockdown attenuated prodigiosin-mediated p53-reporter activation, ΔNp73 downregulation, p73 activation, and cell death. Collectively, our findings highlight the previously uncharacterized use of p73-activating therapeutics to target CRCSCs. Cancer Res; 76(7); 1989-99. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26759239     DOI: 10.1158/0008-5472.CAN-14-2430

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  p53 family members regulate cancer stem cells.

Authors:  Subhasree Basu; Maureen E Murphy
Journal:  Cell Cycle       Date:  2016-04-08       Impact factor: 4.534

Review 2.  Reviving the guardian of the genome: Small molecule activators of p53.

Authors:  Daniel Nguyen; Wenjuan Liao; Shelya X Zeng; Hua Lu
Journal:  Pharmacol Ther       Date:  2017-03-27       Impact factor: 12.310

3.  Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.

Authors:  Shengliang Zhang; Lanlan Zhou; Wafik S El-Deiry
Journal:  Mol Cancer Res       Date:  2022-04-01       Impact factor: 5.852

4.  Prodigiosin-Functionalized Probiotic Ghosts as a Bioinspired Combination Against Colorectal Cancer Cells.

Authors:  Nessrin Saleh; Hoda E Mahmoud; Hoda Eltaher; Maged Helmy; Labiba El-Khordagui; Ahmed A Hussein
Journal:  Probiotics Antimicrob Proteins       Date:  2022-08-28       Impact factor: 5.265

Review 5.  Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.

Authors:  Liz J Hernández Borrero; Wafik S El-Deiry
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2021-04-29       Impact factor: 11.414

Review 6.  Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness.

Authors:  David J Olivos; Lindsey D Mayo
Journal:  Int J Mol Sci       Date:  2016-11-26       Impact factor: 5.923

7.  Inhibitory Growth of Oral Squamous Cell Carcinoma Cancer via Bacterial Prodigiosin.

Authors:  Ming-Fang Cheng; Chun-Shu Lin; Yu-Hsin Chen; Ping-Jyun Sung; Shian-Ren Lin; Yi-Wen Tong; Ching-Feng Weng
Journal:  Mar Drugs       Date:  2017-07-15       Impact factor: 5.118

8.  Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1.

Authors:  Jung-Chen Su; Chuan-Hsun Chang; Szu-Hsien Wu; Chung-Wai Shiau
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

Review 9.  Intestinal microbiota: a novel perspective in colorectal cancer biotherapeutics.

Authors:  Chenbo Ding; Wendong Tang; Xiaobo Fan; Guoqiu Wu
Journal:  Onco Targets Ther       Date:  2018-08-13       Impact factor: 4.147

Review 10.  Production and Potential Applications of Bioconversion of Chitin and Protein-Containing Fishery Byproducts into Prodigiosin: A Review.

Authors:  San-Lang Wang; Van Bon Nguyen; Chien Thang Doan; Thi Ngoc Tran; Minh Trung Nguyen; Anh Dzung Nguyen
Journal:  Molecules       Date:  2020-06-13       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.